Reports Q2 revenue EUR 1.205M vs EUR 930M last year. “As we continue to advance our Axiomer RNA editing platform technology and pipeline with an initial focus on liver-originated diseases, we were very pleased to announce the divestment of our sepofarsen and ultevursen programs to Thea, where they will continue the development of those programs for patients with rare genetic eye disease,” said Daniel A. de Boer, Chief Executive Officer of ProQR. “Over the next several quarters, we anticipate presenting and publishing additional preclinical data including for our first two pipeline programs, AX-0810 for patients suffering from cholestatic diseases and AX-1412 for patients with cardiovascular risk. Along with our preclinical proof of concept data for the platform, a partnership with Eli Lilly, a leading IP position, and cash runway into mid-2026, ProQR is well positioned to execute on our strategy.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRQR:
- ProQR Announces Second Quarter 2023 Operating and Financial Results
- ProQR Therapeutics to divest sepofarsen, ultevursen assets to Laboratoires Thea
- ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
- ProQR Therapeutics presents data on Axiomer RNA Editing technology
- ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit